Tumor Board Discussion

Panelist(s)

• 

  Jonathan David Spicer, MD, PhD, FRCSC

  Associate Professor of Surgery
  Division of Thoracic Surgery, McGill University
  Montreal, Quebec, Canada

  Disclosure(s): Amgen: Advisory Board (Ongoing), Speaker (Ongoing); Astrazeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); CLS Therapeutics: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eisai: Advisory Board (Terminated); MSD: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Protalix Biotherapeutics: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Regeneron: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Roche: Advisory Board (Terminated), Consultant (Terminated), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); xenetic biosciences: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
• 

  Brendon Stiles, MD

  Montefiore Health System / Albert Einstein School of Medicine
  Bronx, New York, United States

  Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
• 

  Linda W. Martin, MD, MPH

  Section Chief, Thoracic Surgery; Professor of Surgery
  University of Virginia
  Charlottesville, Virginia, United States

  Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ethicon: Speaker (Ongoing); Genentech: Advisory Board (Ongoing), Speaker (Ongoing); ontarget laboratories: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)